Antibodies | The Evolution of Monoclonal Antibodies in COVID-19 Therapy: From Early Success to Immune Escape and Future Directions

This article systematically reviews the dynamic changes in the clinical efficacy of monoclonal antibodies against different SARS-CoV-2 variants, providing critical theoretical foundations for studying resistance mechanisms in antiviral therapies and developing next-generation antibody strategies.

 

Literature Overview

The article, 'The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives,' published in the journal Antibodies, systematically explores the application trajectory of neutralizing and immunomodulatory monoclonal antibodies at different stages of COVID-19. The paper reviews the transition from early effective control of the Alpha and Delta variants to the clinical reality that widespread immune escape by Omicron lineages has rendered most antibodies ineffective. It further proposes that future efforts should focus on broadly neutralizing antibodies targeting conserved epitopes and novel delivery platforms. The study also emphasizes the importance of pharmaceutical care and antimicrobial stewardship during pandemics, offering a multidimensional perspective for optimizing subsequent treatment strategies.

Background Knowledge

1. The key challenge in COVID-19 that this study addresses is how to maintain the clinical utility of passive immunotherapies amid continuous viral evolution, especially in high-risk and immunocompromised populations to prevent progression to severe disease. 2. The current bottleneck in spike (S) protein research lies in antigenic drift caused by its high mutation rate, particularly dense mutations in the receptor-binding domain (RBD) (e.g., K417N, T478K, N501Y), which significantly weaken the binding capacity of neutralizing antibodies targeting this region, rendering most first-generation mAbs rapidly ineffective. 3. The research angle integrates virology, clinical pharmacology, and public health strategies to analyze the root causes of neutralizing antibody failure, proposing next-generation therapeutic approaches that target host factors (e.g., IL-6R) and conserved viral epitopes. Additionally, the article introduces post-acute sequelae of SARS-CoV-2 (PASC or 'long COVID') as a potential intervention endpoint, expanding the long-term value assessment of mAbs.

 

 

Research Methods and Experiments

The authors employed a narrative review approach, systematically integrating published clinical trial data (e.g., BLAZE-1, RECOVERY, COMET-ICE), real-world evidence, and structural biology studies to evaluate the neutralizing activity and clinical outcomes of different generations of monoclonal antibodies. By comparing in vitro pseudovirus neutralization results and regulatory authorizations for various antibodies (e.g., bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab) before and during the Omicron era, the study reveals a direct correlation between accumulated mutations and loss of efficacy. The research also analyzes the survival benefit of the immunomodulatory antibody tocilizumab in the RECOVERY and REMAP-CAP trials, confirming its mechanism is independent of spike protein variants.

Key Conclusions and Perspectives

• First-generation neutralizing antibodies targeting the RBD significantly reduced hospitalization risk during the Alpha/Delta waves, but widespread mutations in Omicron sublineages rapidly rendered them ineffective, indicating that single-site or RBD-focused targeting strategies are vulnerable to antigenic drift. Future development should prioritize broadly neutralizing antibodies (bnAbs) targeting conserved regions such as the S2 subunit
• Although sotrovimab targets a non-RBD conserved epitope and retains activity against BA.1, escape by BA.2 and subsequent BQ.1.1/XBB lineages demonstrates that even conserved sites face selective pressure. Combining multi-epitope targeting or enhancing Fc effector functions may improve durability
• Tocilizumab, an IL-6 pathway inhibitor, continues to show clear survival benefits in severe stages, as its mechanism does not depend on viral antigens, highlighting the stability advantage of host-directed therapies against variants and supporting its continued use in managing cytokine storms
• Future platforms such as mRNA-encoded antibodies or inhaled delivery could overcome the cold-chain requirements and intravenous infusion limitations of traditional mAbs, improving accessibility and mucosal concentrations, offering new long-acting preventive strategies for high-risk populations

Research Significance and Prospects

The study emphasizes that monoclonal antibody clinical use must be integrated with real-time genomic surveillance to establish dynamic updating mechanisms in response to antigenic drift. For drug development, priority should be given to screening broadly neutralizing antibodies targeting conserved epitopes, using structure-guided design to enhance resistance to immune escape. In clinical monitoring, enhanced tracking of viral load and variants in immunocompromised individuals is needed to guide personalized mAb use. Furthermore, the potential preventive role against long COVID offers a new endpoint for early antiviral interventions, driving prospective study designs.

 

 

Conclusion

From a translational research perspective, monoclonal antibodies have undergone a dynamic shift during the COVID-19 pandemic—from 'rapidly deployed life-saving drugs' to therapies limited by viral evolution. This trajectory highlights the challenges posed by the high mutability of RNA viruses to targeted therapies and drives the scientific community toward more robust strategies, including broadly neutralizing antibodies, host-targeted interventions, and novel delivery systems. A deeper understanding of SARS-CoV-2 variant mechanisms has not only optimized current treatment algorithms but also provided a paradigm for responding to future emerging infectious diseases. In the endemic phase, integrating viral surveillance, pharmaceutical stewardship, and innovative platforms will be key to sustaining the clinical value of mAbs. This study lays the foundation for a more adaptive treatment framework within the COVID-19 care system, with profound implications for protecting high-risk populations and preventing long COVID.

 

Francesco Ferrara, Flavia De Berardinis, Manlio Scognamiglio, and Andrea Zovi. The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives. Antibodies.